ProfileGDS4814 / ILMN_1885040
TitleOvarian cancer xenograft tumor response to trastuzumab and pertuzumab
OrganismHomo sapiens


none trastuzumab pertuzumab trastuzumab and pertuzumab GSM780707 GSM780708 GSM780709 GSM780719 GSM780720 GSM780721 GSM780710 GSM780711 GSM780712 GSM780722 GSM780723 GSM780724 GSM780713 GSM780714 GSM780715 GSM780725 GSM780726 GSM780727 GSM780716 GSM780717 GSM780718 GSM780728 GSM780729 20% 9% 15% 7% 2% 47% 12% 25% 40% 47% 14% 22% 28% 1% 42% 40% 15% 45% 15% 6% 16% 28% 32% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM780707Untreated after 4 days (C1_1)43.601120
GSM780708Untreated after 4 days (C2_1)40.96129
GSM780709Untreated after 4 days (C3_1)42.476115
GSM780719Untreated after 4 days (C1_2)40.23637
GSM780720Untreated after 4 days (C2_2)37.81222
GSM780721Untreated after 4 days (C3_2)49.661847
GSM780710Trastuzumab treated after 4 days (T1_1)41.683712
GSM780711Trastuzumab treated after 4 days (T2_1)44.613125
GSM780712Trastuzumab treated after 4 days (T3_1)47.649540
GSM780722Trastuzumab treated after 4 days (T1_2)49.506147
GSM780723Trastuzumab treated after 4 days (T2_2)42.275714
GSM780724Trastuzumab treated after 4 days (T3_2)44.009122
GSM780713Pertuzumab treated after 4 days (P1_1)45.117128
GSM780714Pertuzumab treated after 4 days (P2_1)35.84381
GSM780715Pertuzumab treated after 4 days (P3_1)48.218942
GSM780725Pertuzumab treated after 4 days (P1_2)47.745340
GSM780726Pertuzumab treated after 4 days (P2_2)42.568315
GSM780727Pertuzumab treated after 4 days (P3_2)49.021345
GSM780716Trastuzumab and Pertuzumab treated after 4 days (TP1_1)42.45415
GSM780717Trastuzumab and Pertuzumab treated after 4 days (TP2_1)39.83266
GSM780718Trastuzumab and Pertuzumab treated after 4 days (TP3_1)42.728116
GSM780728Trastuzumab and Pertuzumab treated after 4 days (TP1_2)45.127528
GSM780729Trastuzumab and Pertuzumab treated after 4 days (TP2_2)46.003832